iPSC Tech Help Clinic: Human iPSC-Derived Cardiomyocytes
Presented by: Jamie Bhagwan, Phd
iPSC Tech Help Clinic: Human iPSC-Derived Cardiomyocytes
Build high-quality cardiotoxicity models in 7 days.
Ensure confidence in your workflow with high-quality axoCellsTM ventricular cardiomyocytes differentiated from human induced pluripotent stem cells (iPSCs). Derived from consenting donor fibroblasts, our ventricular cardiomyocytes have been specifically developed for use in drug validation and cardiotoxicity screening.
With Axol, you can rely on physiologically relevant cardiomyocytes that can detect action potential duration prolongation and triangulation associated with hERG block and torsades de pointes (TdP), and have been validated against all 28 CiPA compounds, correctly identifying cardiotoxic liability. Further MEA studies have confirmed the correct response to all the major classes of cardioactive drugs. With our functionally relevant and mature cardiomyocytes, you can build robust in vitro models for drug validation and cardiotoxicity screening.